<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://mutage.oxfordjournals.org">
<title>Mutagenesis - Advance Access</title>
<link>http://mutage.oxfordjournals.org</link>
<description>Mutagenesis - RSS feed of articles</description>
<prism:eIssn>1464-3804</prism:eIssn>
<prism:publicationName>Mutagenesis</prism:publicationName>
<prism:issn>0267-8357</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://mutage.oxfordjournals.org/cgi/content/short/gep024v1?rss=1" />
  <rdf:li rdf:resource="http://mutage.oxfordjournals.org/cgi/content/short/gep016v1?rss=1" />
  <rdf:li rdf:resource="http://mutage.oxfordjournals.org/cgi/content/short/gep021v1?rss=1" />
  <rdf:li rdf:resource="http://mutage.oxfordjournals.org/cgi/content/short/gep025v1?rss=1" />
  <rdf:li rdf:resource="http://mutage.oxfordjournals.org/cgi/content/short/gep023v1?rss=1" />
  <rdf:li rdf:resource="http://mutage.oxfordjournals.org/cgi/content/short/gep022v1?rss=1" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://mutage.oxfordjournals.org/cgi/content/short/gep024v1?rss=1">
<title><![CDATA[The rat bone marrow micronucleus test--study design and statistical power]]></title>
<link>http://mutage.oxfordjournals.org/cgi/content/short/gep024v1?rss=1</link>
<description><![CDATA[
<p>Although the rodent bone marrow micronucleus test has been in routine use for over 20 years, little work has been published to support its experimental design and all this has used the mouse rather than the rat. When it was decided to change the strain of rat routinely used in this laboratory to the Han Wistar, a preliminary study was performed to investigate the possible factors influencing experimental variability and to use statistical tools to examine possible study designs. Subsequently, a historical database comprising of vehicle controls accumulated from 65 studies was used to establish test acceptance criteria and a strategy for analysing equivocal results. The following conclusions were made: (i) no statistically significant differences were observed in experimental variability within or between control animals; although not statistically significant, the majority of experimental variability seen was found to be between separate counts on the same slide, with minimal differences found between duplicate slides from the same rat or between individual rats; (ii) power analyses showed that, if an equivocal result is obtained after scoring 2000 immature erythrocytes (IE), it is appropriate to re-code the slides and score an additional 4000 IE, i.e. analysing a total of 6000 IE; no meaningful increase in statistical power is gained by scoring &gt;6000 IE; this is consistent with the variability observed between separate counts on the same slide; (iii) there was no significant difference between the control micronucleated immature erythrocyte (MIE) values at 24 and 48 h after dosing or between males and females; therefore, if an unusually low control value at either time point results in apparent small increases in MIE in a treated group, it is valid to pool control values from both time points for clarification and (iv) similar statistical power can be achieved by scoring 2000 IE from seven rats or 4000 IE from five rats, respectively. However, this is based only on control animals and does not consider possible differences in responses between animals to treatment with a potential genotoxin. In order to minimize the possible influence of responders and non-responders, the preferred study design in this laboratory is to score 2000 IE from groups of seven rats. Study data obtained over time confirmed observations made in the control study. Also from an ethical viewpoint, clarifying equivocal responses by combining control data from the 24- and 48-h time points and/or increasing the number of IE scored per animal has minimized the numbers of repeat studies necessary to determine the genotoxic status of a novel compound. However, before any laboratory can use these procedures, experimental data must be generated to demonstrate their validity.</p>
]]></description>
<dc:creator><![CDATA[Hayes, J., Doherty, A. T., Adkins, D. J., Oldman, K., O'Donovan, M. R.]]></dc:creator>
<dc:date>2009-06-30</dc:date>
<dc:identifier>info:doi/10.1093/mutage/gep024</dc:identifier>
<dc:title><![CDATA[The rat bone marrow micronucleus test--study design and statistical power]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:publicationDate>2009-06-30</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://mutage.oxfordjournals.org/cgi/content/short/gep016v1?rss=1">
<title><![CDATA[Flavonoids inhibit the genotoxicity of hydrogen peroxide (H2O2) and of the food mutagen 2-amino-3-methylimadazo[4,5-f]-quinoline (IQ) in lymphocytes from patients with inflammatory bowel disease (IBD)]]></title>
<link>http://mutage.oxfordjournals.org/cgi/content/short/gep016v1?rss=1</link>
<description><![CDATA[
<p>Inflammatory bowel disease (IBD) including Crohn's disease (CD) and ulcerative colitis (UC) is a chronic inflammatory gastrointestinal autoimmune condition with an inappropriate immune response. We investigated DNA damage induced <I>in vitro</I> in lymphocytes from IBD patients caused by oxidative stress through H<SUB>2</SUB>O<SUB>2</SUB> and 2-amino-3-methylimidazo[4,5-<I>f</I>]quinoline (IQ) and whether the plant flavonoids, quercetin and epicatechin, found in fruits, tea and soybeans could effectively reduce such stress. Lymphocytes from IBD patients and healthy volunteers were treated with 50 &micro;g/ml H<SUB>2</SUB>O<SUB>2</SUB> or IQ in the presence of quercetin (0&ndash;250 &micro;g/ml) or epicatechin (0&ndash;100 &micro;g/ml). Flavonoid supplementation (250 &micro;M quercetin or 100 &micro;M epicatechin) caused an overall significant decrease of induced DNA damage resulting in a 48.6% (<I>P</I> &lt; 0.001) reduction of H<SUB>2</SUB>O<SUB>2</SUB>-induced and a 43% (<I>P</I> &lt; 0.001) reduction of IQ-induced DNA damage within the patient groups; for the control groups, reductions in DNA damage were 35.2 and 57.1%, respectively (both, <I>P</I> &lt; 0.001). There was less induced DNA damage within lymphocytes from UC patients compared to CD patients for both series of experiments (H<SUB>2</SUB>O<SUB>2</SUB> and quercetin, IQ and epicatechin). In conclusion, flavonoids dramatically reduced oxidative stress <I>in vitro</I> in lymphocytes from IBD patients and healthy individuals. Thus, flavonoids could be very effective in the treatment of oxidative stress and encouraged in the diet of IBD patients.</p>
]]></description>
<dc:creator><![CDATA[Najafzadeh, M., Reynolds, P. D., Baumgartner, A., Anderson, D.]]></dc:creator>
<dc:date>2009-06-24</dc:date>
<dc:identifier>info:doi/10.1093/mutage/gep016</dc:identifier>
<dc:title><![CDATA[Flavonoids inhibit the genotoxicity of hydrogen peroxide (H2O2) and of the food mutagen 2-amino-3-methylimadazo[4,5-f]-quinoline (IQ) in lymphocytes from patients with inflammatory bowel disease (IBD)]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:publicationDate>2009-06-24</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://mutage.oxfordjournals.org/cgi/content/short/gep021v1?rss=1">
<title><![CDATA[Increasing the resolution of the comet assay using fluorescent in situ hybridization--a review]]></title>
<link>http://mutage.oxfordjournals.org/cgi/content/short/gep021v1?rss=1</link>
<description><![CDATA[
<p>The comet assay (single-cell gel electrophoresis) is now the most popular method for measuring low levels of damage in cellular DNA. Cells are embedded in agarose on a microscope slide and lysed to produce nucleoids of supercoiled DNA attached to the nuclear matrix. Breaks in the DNA relax the supercoiling and allow DNA loops to expand, and on electrophoresis to move towards the anode, giving the appearance of a comet tail. The % of DNA in the tail reflects the break frequency. Digestion of nucleoid DNA with lesion-specific endonucleases extends the usefulness of the method to investigate different kinds of damage. DNA repair can be studied by treating cells with a genotoxic agent, incubating them and using the comet assay to follow the removal of the damage. An important feature of the assay is that damage is detected at the level of individual cells. The comet assay can be combined with fluorescent <I>in situ</I> hybridization, using labelled probes to particular DNA sequences, and DNA damage and repair can be examined at an even finer level of resolution. Here, we provide a general review of the technique, answer some technical and theoretical questions and give examples of applications of the method.</p>
]]></description>
<dc:creator><![CDATA[Shaposhnikov, S., Frengen, E., Collins, A. R.]]></dc:creator>
<dc:date>2009-06-17</dc:date>
<dc:identifier>info:doi/10.1093/mutage/gep021</dc:identifier>
<dc:title><![CDATA[Increasing the resolution of the comet assay using fluorescent in situ hybridization--a review]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:publicationDate>2009-06-17</prism:publicationDate>
<prism:section>REVIEWS</prism:section>
</item>

<item rdf:about="http://mutage.oxfordjournals.org/cgi/content/short/gep025v1?rss=1">
<title><![CDATA[RUNX2 mutations in Chinese patients with cleidocranial dysplasia]]></title>
<link>http://mutage.oxfordjournals.org/cgi/content/short/gep025v1?rss=1</link>
<description><![CDATA[
<p>Cleidocranial dysplasia (CCD) is an autosomal dominant bone disease in humans caused by haploinsufficiency of the <I>RUNX2</I> gene. The <I>RUNX2</I> has two major isoforms derived from P1 and P2 promoters. Over 90 mutations of <I>RUNX2</I> have been reported associated with CCD. In our study, DNA samples of nine individuals from three unrelated CCD families were collected and screened for all exons of <I>RUNX2</I> and 2 kb of P1 and P2 promoters. We identified two point mutations in the <I>RUNX2</I> gene in Case 1, including a nonsense mutation (c.577C&gt;T) that has been reported previously and a silent substitution (c.240G&gt;A). <I>In vitro</I> studies demonstrated that c.577C&gt;T mutation led to truncated RUNX2 protein production and diminished stimulating effects on mouse <I>osteocalcin</I> promoter activity when compared with full-length <I>Runx2</I>-II and <I>Runx2</I>-I isoforms. These results confirm that loss of function <I>RUNX2</I> mutation (c.577C&gt;T) in Case 1 family is responsible for its CCD phenotype.</p>
]]></description>
<dc:creator><![CDATA[Li, Y., Pan, W., Xu, W., He, N., Chen, X., Liu, H., Darryl Quarles, L., Zhou, H., Xiao, Z.]]></dc:creator>
<dc:date>2009-06-10</dc:date>
<dc:identifier>info:doi/10.1093/mutage/gep025</dc:identifier>
<dc:title><![CDATA[RUNX2 mutations in Chinese patients with cleidocranial dysplasia]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:publicationDate>2009-06-10</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://mutage.oxfordjournals.org/cgi/content/short/gep023v1?rss=1">
<title><![CDATA[Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells]]></title>
<link>http://mutage.oxfordjournals.org/cgi/content/short/gep023v1?rss=1</link>
<description><![CDATA[
<p>Plumbagin, a naphthoquinone derived from the medicinal plant <I>Plumbago zeylanica</I> has been shown to exert anticancer and anti-proliferative activities in cells in culture as well as animal tumor models. In our previous paper, we have reported the cytotoxic action of plumbagin in plasmid pBR322 DNA as well as human peripheral blood lymphocytes through a redox mechanism involving copper. Copper has been shown to be capable of mediating the action of several plant-derived compounds through production of reactive oxygen species (ROS). The objective of the present study was to determine whether plumbagin induces apoptosis in human cancer cells through the same mechanism which we proposed earlier. Using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt assay, 3-(4,5-B-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay for cell growth inhibition, histone/DNA ELISA, homogeneous caspase-3/7 assay for apoptosis as well as alkaline comet assay for DNA single-strand breaks detection in this report, we confirm that plumbagin causes effective cell growth inhibition, induces apoptosis and generates single-strand breaks in cancer cells. Incubation of cancer cells with scavengers of ROS and neocuproine inhibited the cytotoxic action of plumbagin proving that generation of ROS and Cu(I) are the critical mediators in plumbagin-induced cell growth inhibition. This study is the first to investigate the copper-mediated anticancer mechanism of plumbagin in human cancer cells and these properties of plumbagin could be further explored for the development of anticancer agents with higher therapeutic indices, especially for skin cancer.</p>
]]></description>
<dc:creator><![CDATA[Nazeem, S., Azmi, A. S., Hanif, S., Ahmad, A., Mohammad, R. M., Hadi, S. M., Kumar, K. S.]]></dc:creator>
<dc:date>2009-06-07</dc:date>
<dc:identifier>info:doi/10.1093/mutage/gep023</dc:identifier>
<dc:title><![CDATA[Plumbagin induces cell death through a copper-redox cycle mechanism in human cancer cells]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:publicationDate>2009-06-07</prism:publicationDate>
<prism:section>Article</prism:section>
</item>

<item rdf:about="http://mutage.oxfordjournals.org/cgi/content/short/gep022v1?rss=1">
<title><![CDATA[Is tamoxifen a genotoxic carcinogen in women?]]></title>
<link>http://mutage.oxfordjournals.org/cgi/content/short/gep022v1?rss=1</link>
<description><![CDATA[
<p>The anti-oestrogen tamoxifen, which is widely used in the treatment of breast cancer and is also approved for the prevention of this disease, causes an increased incidence of endometrial cancer in women. The ability of tamoxifen to induce endometrial tumours and the underlying carcinogenic mechanisms have been a subject of intense interest over the last ~20 years. They are central to the assessment of risks versus benefits for the drug, especially in a chemopreventive context. This review outlines the clinical justification for using tamoxifen as a chemopreventive agent and describes the genotoxic mechanisms considered responsible for tamoxifen-induced tumours in rat liver and how these might relate to women. In rat hepatic tissue, tamoxifen is metabolically activated via -hydroxylation and sulphate conjugation to give a reactive species that binds to DNA predominantly at the <I>N</I><sup>2</sup>-position of guanine, producing pro-mutagenic lesions. Whether tamoxifen&ndash;DNA adducts contribute similarly to the development of cancers in women depends on whether they can be formed in human tissues and the type of specific molecular and cellular responses they induce, if present. This review discusses the current data relating to these issues and highlights areas where further research is needed.</p>
]]></description>
<dc:creator><![CDATA[Brown, K.]]></dc:creator>
<dc:date>2009-06-07</dc:date>
<dc:identifier>info:doi/10.1093/mutage/gep022</dc:identifier>
<dc:title><![CDATA[Is tamoxifen a genotoxic carcinogen in women?]]></dc:title>
<dc:publisher>Oxford University Press</dc:publisher>
<prism:publicationDate>2009-06-07</prism:publicationDate>
<prism:section>REVIEWS</prism:section>
</item>

</rdf:RDF>